Display options
Cite
Qian X, Ma C, Hoffmann TK, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. Springerplus. 2015;4:208doi: 10.1186/s40064-015-0988-5.
Qian, X., Ma, C., Hoffmann, T. K., Kaufmann, A. M., & Albers, A. E. (2015). Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. SpringerPlus, 4208. https://doi.org/10.1186/s40064-015-0988-5
Qian, Xu, et al. "Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety." SpringerPlus vol. 4 (2015): 208. doi: https://doi.org/10.1186/s40064-015-0988-5
Qian X, Ma C, Hoffmann TK, Kaufmann AM, Albers AE. Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. Springerplus. 2015 May 01;4:208. doi: 10.1186/s40064-015-0988-5. eCollection 2015. PMID: 25977896; PMCID: PMC4422827.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2015 May 01;4:208. doi: 10.1186/s40064-015-0988-5. eCollection 2015.

Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety.

SpringerPlus

Xu Qian, Chenming Ma, Thomas K Hoffmann, Andreas M Kaufmann, Andreas E Albers

Affiliations

  1. Department of Otolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany.
  2. Department of Histology and Embryology, Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou medical University, Wenzhou, China.
  3. Department of Otolaryngology, Head and Neck Surgery, University of Ulm, Ulm, Germany.
  4. Clinic for Gynecology, Charité-Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany.

PMID: 25977896 PMCID: PMC4422827 DOI: 10.1186/s40064-015-0988-5

Abstract

BACKGROUND: The objective of this study was to compare the efficacy and safety of taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) with cisplatin plus fluorouracil (PF) regimen by a meta-analysis of data retrieved from the literature.

METHODS: Seven randomized clinical trials were identified, which included patients with advanced head and neck cancer who underwent induction chemotherapy with either a Tax-PF or PF protocol. The outcomes included the 3-year and 5-year overall survival (OS) and progression-free survival (PFS), overall response rate (ORR) and different types of adverse events.

RESULTS: The 3-year OS rate (HR: 1.14; 95% CI: 1.03 to 1.25; P = 0.008), 3-year PFS rate (HR: 1.24; 95% CI: 1.08 to 1.43; P = 0.002), 5-year OS rate (HR: 1.30; 95% CI, 1.09 to 1.55;P = 0.003), 5-year PFS rate (HR: 1.39; 95% CI, 1.14 to 1.70; P = 0.001) and ORR to chemotherapy (OR 1.66; 95% CI, 1.35 to 2.05; P < 0.001) of the patients in the Tax-PF group were statistically superior to those in the PF group. In terms of toxicities, the incidence of febrile neutropenia (OR 2.36; 95% CI, 1.62 to 3.46; P < 0.001), alopecia (OR 8.22; 95% CI, 3.99 to 16.92; P < 0.001), diarrhea (OR 1.57; 95% CI, 1.05 to 2.36; P = 0.03) and leukopenia (OR 2.79; 95% CI, 1.86 to 4.21; P < 0.001) was higher in the Tax-PF group.

CONCLUSION: The Tax-PF induction chemotherapy improved PFS and OS, and the ORR was better as compared to PF-based therapy regimens at the cost of a higher incidence of adverse events.

Keywords: Cisplatin; Docetaxel; Fluoruracil; Head and neck carcinoma; Induction chemotherapy; Survival

References

  1. Lancet. 1998 Aug 22;352(9128):609-13 - PubMed
  2. Lancet Oncol. 2011 Feb;12(2):153-9 - PubMed
  3. Anticancer Res. 2014 Jul;34(7):3765-73 - PubMed
  4. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  5. Oncologist. 2000;5(3):199-208 - PubMed
  6. Anticancer Res. 2014 Oct;34(10):5709-14 - PubMed
  7. Stat Med. 1998 Dec 30;17(24):2815-34 - PubMed
  8. Oncol Rep. 2013 May;29(5):1777-84 - PubMed
  9. J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 - PubMed
  10. PLoS One. 2012;7(12):e51526 - PubMed
  11. J Cancer Res Clin Oncol. 2014 Jul;140(7):1151-8 - PubMed
  12. Radiother Oncol. 2009 Jul;92(1):4-14 - PubMed
  13. Eur J Cancer. 2014 Oct;50(15):2636-48 - PubMed
  14. Cancer Lett. 2014 Apr 28;346(1):53-62 - PubMed
  15. Oral Oncol. 2014 Sep;50(9):888-94 - PubMed
  16. J Natl Cancer Inst. 2009 Apr 1;101(7):498-506 - PubMed
  17. N Engl J Med. 2007 Oct 25;357(17):1695-704 - PubMed
  18. N Engl J Med. 2007 Oct 25;357(17):1705-15 - PubMed
  19. J Clin Oncol. 2013 Aug 10;31(23):2844-6 - PubMed
  20. Ann Oncol. 2014 Jan;25(1):216-25 - PubMed
  21. Oral Oncol. 2014 Nov;50(11):1041-8 - PubMed
  22. Control Clin Trials. 1996 Feb;17(1):1-12 - PubMed
  23. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  24. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  25. Lancet. 2008 May 17;371(9625):1695-709 - PubMed
  26. Curr Opin Oncol. 2014 May;26(3):247-51 - PubMed
  27. J Clin Oncol. 2014 Jan 20;32(3):259 - PubMed
  28. J Clin Oncol. 2013 Aug 10;31(23 ):2854-60 - PubMed
  29. J Clin Oncol. 2005 Dec 1;23(34):8636-45 - PubMed

Publication Types